ES2238941T1 - Solvato de hemitartrato de zolpidem. - Google Patents
Solvato de hemitartrato de zolpidem.Info
- Publication number
- ES2238941T1 ES2238941T1 ES04010435T ES04010435T ES2238941T1 ES 2238941 T1 ES2238941 T1 ES 2238941T1 ES 04010435 T ES04010435 T ES 04010435T ES 04010435 T ES04010435 T ES 04010435T ES 2238941 T1 ES2238941 T1 ES 2238941T1
- Authority
- ES
- Spain
- Prior art keywords
- zolpidem hemitartrate
- hydrate
- solvate
- zolpidem
- hemitartrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VXRDAMSNTXUHFX-CEAXSRTFSA-N zolpidem tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1.N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 VXRDAMSNTXUHFX-CEAXSRTFSA-N 0.000 title claims abstract 26
- 239000012453 solvate Substances 0.000 title claims abstract 12
- 150000004683 dihydrates Chemical class 0.000 claims abstract 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims abstract 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract 3
- 150000004682 monohydrates Chemical class 0.000 claims abstract 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 2
- 150000004685 tetrahydrates Chemical class 0.000 claims 2
- 150000004684 trihydrates Chemical class 0.000 claims 2
- VDGOTZAKEQIVOP-UHFFFAOYSA-N C(CCC)O.C(C(O)C(O)C(=O)O)(=O)O.C(CCC)O Chemical compound C(CCC)O.C(C(O)C(O)C(=O)O)(=O)O.C(CCC)O VDGOTZAKEQIVOP-UHFFFAOYSA-N 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 claims 1
- 229960001475 zolpidem Drugs 0.000 claims 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N Butanol Natural products CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 abstract 1
- SRDBTVMAHGZQGD-UHFFFAOYSA-N O.O.O.O.O.O.O Chemical compound O.O.O.O.O.O.O SRDBTVMAHGZQGD-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Suspension Of Electric Lines Or Cables (AREA)
- Amplifiers (AREA)
- Supply Devices, Intensifiers, Converters, And Telemotors (AREA)
- Other Liquid Machine Or Engine Such As Wave Power Use (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Solvato de hemitartrato de zolpidem. El solvato es un hidrato. El hidrato es un monohidrato, dihidrato. trihidrato.tetrahidrato. El solvato se selecciona de entre el grupo constituido por isopropanol de hemitartrato de zolpidem, butanol de hemitartrato de zolpidem, acetato de etilo de hemitartrato de zolpidem y acetona de hemitartrato de zolpidem.
Claims (24)
1. Solvato de hemitartrato de zolpidem.
2. Solvato de hemitartrato de zolpidem según la
reivindicación 1, en el que solvato es un hidrato.
3. Hidrato según la reivindicación 2, en el que
el hidrato es un monohidrato.
4. Hidrato según la reivindicación 2, en el que
el hidrato es un dihidrato.
5. Hidrato según la reivindicación 2, en el que
el hidrato es un trihidrato.
6. Hidrato según la reivindicación 2, en el que
el hidrato es un tetrahidrato.
7. Hidrato según la reivindicación 2, en el que
el hidrato es un hidrato 2/3.
8. Hidrato según la reivindicación 2 ó 3, en el
que el hemitartrato de zolpidem es un monohidrato de Forma D.
9. Hidrato según la reivindicación 8, en el que
el hemitartrato de zolpidem es una Forma D, en el que el contenido
de agua está comprendido entre aproximadamente 2,3% y
aproximadamente 2,7% en peso.
10. Solvato según la reivindicación 1, en el que
el hemitartrato de zolpidem es un hemietanolato de Forma D.
11. Solvato según la reivindicación 10, en el que
el solvato se selecciona de entre el grupo constituido por
isopropanol de hemitartrato de zolpidem, butanol de hemitartrato de
zolpidem, acetato de etilo de hemitartrato de zolpidem y acetona de
hemitartrato de zolpidem.
12. Hidrato según la reivindicación 2 ó 4, en el
que el hemitartrato de zolpidem es un dihidrato de Forma E.
13. Hidrato según la reivindicación 2 ó 5, en el
que el hemitartrato de zolpidem es un trihidrato de Forma E.
14. Hidrato según la reivindicación 2 ó 6, en el
que el hemitartrato de zolpidem es un tetrahidrato de Forma E.
15. Hidrato según la reivindicación 2, en el que
el hemitartrato de zolpidem es la Forma E y el contenido en agua
está comprendido entre aproximadamente 5,0% y aproximadamente 8,5%
en peso.
16. Solvato según la reivindicación 1, en el que
el hemitartrato de zolpidem es un metalonato de Forma F.
17. Forma F del hemitartrato de zolpidem según la
reivindicación 16, en el que el contenido de metanol es de
aproximadamente 5,5% en peso.
18. Solvato según la reivindicación 1, en el que
el hemitartrato de zolpidem es un dihidrato de Forma G.
19. Hidrato según la reivindicación 2 ó 4, en el
que el hemitartrato de zolpidem es un dihidrato de Forma L.
20. Hidrato según la reivindicación 19, en el que
el contenido de agua es de aproximadamente 4,3% en peso.
21. Hemitartrato de zolpidem según cualquiera de
las reivindicaciones anteriores, que presenta unas partículas con
un tamaño de hasta 200 micrones tal como se mide mediante
difracción láser.
22. Hemitartrato de zolpidem según la
reivindicación 21, que presenta unas partículas con un tamaño de
hasta aproximadamente 50 micrones.
23. Composición farmacéutica que comprende una
cantidad terapéuticamente efectiva de hemitartrato de zolpidem según
cualquiera de las reivindicaciones anteriores y un vehículo
farmacéuticamente aceptable.
24. Utilización de un hemitartrato de zolpidem
según cualquiera de las reivindicaciones anteriores, en la
preparación de un medicamento destinado al tratamiento del
insomnio.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19929800P | 2000-04-24 | 2000-04-24 | |
US199298P | 2000-04-24 | ||
US20602500P | 2000-05-22 | 2000-05-22 | |
US206025P | 2000-05-22 | ||
US22536400P | 2000-08-14 | 2000-08-14 | |
US225364P | 2000-08-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2238941T1 true ES2238941T1 (es) | 2005-09-16 |
ES2238941T3 ES2238941T3 (es) | 2007-04-01 |
Family
ID=27394001
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES04010435T Expired - Lifetime ES2238941T3 (es) | 2000-04-24 | 2001-04-24 | Solvato de hemitartrato de zolpidem. |
ES04010651T Expired - Lifetime ES2239558T3 (es) | 2000-04-24 | 2001-04-24 | Hemitartrato de zolpidem micronizado. |
ES01930705T Expired - Lifetime ES2248321T3 (es) | 2000-04-24 | 2001-04-24 | Hemitartrato de zolpidem. |
ES05001922T Expired - Lifetime ES2277301T3 (es) | 2000-04-24 | 2001-04-24 | Solvato de hemitartrato de zolpidem. |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES04010651T Expired - Lifetime ES2239558T3 (es) | 2000-04-24 | 2001-04-24 | Hemitartrato de zolpidem micronizado. |
ES01930705T Expired - Lifetime ES2248321T3 (es) | 2000-04-24 | 2001-04-24 | Hemitartrato de zolpidem. |
ES05001922T Expired - Lifetime ES2277301T3 (es) | 2000-04-24 | 2001-04-24 | Solvato de hemitartrato de zolpidem. |
Country Status (21)
Country | Link |
---|---|
US (8) | US20020077332A1 (es) |
EP (1) | EP1292304B1 (es) |
JP (3) | JP2003531173A (es) |
KR (1) | KR20030069796A (es) |
AT (4) | ATE308324T1 (es) |
AU (2) | AU5721301A (es) |
CA (1) | CA2406982A1 (es) |
CZ (1) | CZ20023775A3 (es) |
DE (7) | DE60125429T2 (es) |
DK (1) | DK1292304T3 (es) |
ES (4) | ES2238941T3 (es) |
HR (1) | HRP20020909A2 (es) |
HU (1) | HUP0300701A2 (es) |
IL (1) | IL152411A0 (es) |
NZ (1) | NZ522015A (es) |
PL (1) | PL358548A1 (es) |
PT (3) | PT1541146E (es) |
SE (1) | SE5292304T3 (es) |
SK (1) | SK16372002A3 (es) |
WO (1) | WO2001080857A1 (es) |
YU (1) | YU79402A (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1370515A2 (en) | 2000-08-29 | 2003-12-17 | Ranbaxy Laboratories, Ltd. | Synthesis of n,n-dimethyl-3-(4-methyl) benzoyl propionamide, a key intermediate of zolpidem |
US6869970B2 (en) | 2002-02-04 | 2005-03-22 | Novartis Ag | Crystalline salt forms of valsartan |
ES2320758T3 (es) | 2002-12-18 | 2009-05-28 | Mallinckrodt Inc. | Sintesis de heteroaril acetamidas. |
WO2004087703A1 (en) * | 2003-03-12 | 2004-10-14 | Sun Pharmaceutical Industries Limited | Process for the preparation of n,n,6-trimethyl-2-(4-methylphenyl)-imidazo[1,2-a]pyridine-3-acetamide |
WO2005010002A1 (en) * | 2003-07-31 | 2005-02-03 | Ranbaxy Laboratories Limited | Process for the synthesis of zolpidem |
EP1715853A4 (en) * | 2004-02-17 | 2012-07-18 | Transcept Pharmaceuticals Inc | COMPOSITIONS FOR THE DISTRIBUTION OF HYPNOTICS IN THE FIELD OF MUNICHCHLEIMHÄUTE AND USE METHOD THEREOF |
US20080262025A1 (en) * | 2004-07-16 | 2008-10-23 | Yatendra Kumar | Processes for the Preparation of Zolpidem and its Hemitartrate |
US20070225322A1 (en) * | 2005-05-25 | 2007-09-27 | Transoral Pharmaceuticals, Inc. | Compositions and methods for treating middle-of-the night insomnia |
US20070287740A1 (en) * | 2005-05-25 | 2007-12-13 | Transcept Pharmaceuticals, Inc. | Compositions and methods of treating middle-of-the night insomnia |
NZ563979A (en) * | 2005-05-25 | 2011-02-25 | Transcept Pharmaceuticals Inc | Solid compositions and methods for treating middle-of-the night insomnia |
BRPI0615357A2 (pt) * | 2005-08-19 | 2011-05-17 | Aventis Pharma Inc | combinação de um agente hipnótico e r (+)-alfa-(2,3-dimetóxi-fenil)-1-[2-(4-fluorofenil)etil]-4-pi peridinometanol e aplicação terapêutica do mesmo |
ES2336142T3 (es) * | 2005-08-19 | 2010-04-08 | Aventis Pharmaceuticals Inc. | Combinacion de un agente hipnotico y un compuesto sustituido, con bis arilo y heteroarilo y aplicacion terapeutica del mismo. |
EP1948655A1 (en) * | 2005-10-03 | 2008-07-30 | Mallinckrodt, Inc. | Process for preparing zolpidem hemitartrate and tartrate polymorphs |
CA2626242A1 (en) * | 2005-10-17 | 2007-04-26 | Mallinckrodt Inc. | Polymorph transformation of zolpidem in tablet matrix |
US20070098788A1 (en) * | 2005-10-28 | 2007-05-03 | Gore Subhash P | Non-benzodiazepine hypnotic compositions |
DK2007752T3 (da) | 2006-03-31 | 2010-11-15 | Janssen Pharmaceutica Nv | Benzimidazol-2-yl-pyrimidiner og -pyraziner som modulatorer af histamin H4-receptoren |
WO2008067549A2 (en) * | 2006-11-30 | 2008-06-05 | Transcept Pharmaceuticals, Inc. | Stabilized zolpidem pharmaceutical compositions |
US20080145425A1 (en) * | 2006-12-15 | 2008-06-19 | Pliva Research & Development Limited | Pharmaceutical composition of zolpidem |
US20100029942A1 (en) * | 2008-06-30 | 2010-02-04 | Sergio Cesco-Cancian | Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives |
US9371311B2 (en) | 2008-06-30 | 2016-06-21 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyrimidine derivatives |
SI3133070T1 (sl) | 2009-11-27 | 2019-11-29 | Genzyme Corp | Eliglustat (GENZ 112638) kot inhibitor sintaze glukozilceramida za uporabo v postopku zdravljenja Fabrjyeve ali Gaucherjeve bolezni, kjer postopek obsega prilagajanje individualnega terapevtskega odmerka metabolizmu P-450 pacienta |
WO2011115069A1 (ja) * | 2010-03-19 | 2011-09-22 | 第一三共株式会社 | 結晶の網羅的探索 |
AU2014225675B2 (en) | 2013-03-06 | 2018-10-04 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyrimidine modulators of the histamine H4 receptor |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4151273A (en) * | 1974-10-31 | 1979-04-24 | The Regents Of The University Of California | Increasing the absorption rate of insoluble drugs |
FR2408345A1 (fr) * | 1976-11-30 | 1979-06-08 | Besins Jean Louis | Nouvelle composition a action anti-conceptionnelle |
US4302446A (en) * | 1979-10-02 | 1981-11-24 | Bristol-Myers Company | Pharmaceutical compositions |
IT1130924B (it) * | 1980-03-06 | 1986-06-18 | Secifarma Spa | Procedimento per la preparazione di spironolattone micronizzato |
DE3018940A1 (de) * | 1980-05-17 | 1981-11-26 | Hoechst Ag, 6000 Frankfurt | Verwendung eines vinylchlorid-pfropf-copolymerisates in der plastisolverarbeitung |
FR2492382A1 (fr) * | 1980-10-22 | 1982-04-23 | Synthelabo | Derives d'imidazo (1,2-a) pyridine, leur preparation et leur application en therapeutique |
FR2525601A1 (fr) * | 1982-04-21 | 1983-10-28 | Synthelabo | Derives d'imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique |
US4675323A (en) * | 1985-08-06 | 1987-06-23 | Synthelabo | Imidazo(1,2-a)quinoline derivatives useful as anxiolytic agents |
SE457326B (sv) * | 1986-02-14 | 1988-12-19 | Lejus Medical Ab | Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa |
FR2600650B1 (fr) * | 1986-06-27 | 1988-09-09 | Synthelabo | Procede de preparation d'imidazopyridines et composes intermediaires |
FR2606410B1 (fr) * | 1986-11-07 | 1989-02-24 | Synthelabo | Imidazopyridines, leur preparation et leur application en therapeutique |
EP0289371B1 (fr) * | 1987-03-27 | 1991-09-25 | Synthelabo | Dérivés d'imidazopyridines, leur préparation et leur application en thérapeutique |
US5271944A (en) * | 1991-04-05 | 1993-12-21 | Biofor, Ltd. | Pharmacologically enhanced formulations |
IT1276522B1 (it) * | 1995-04-07 | 1997-10-31 | Elena Benincasa | Uso dello zolpidem per il trattamento terapeudico di sindromi neuropsichiatriche associate a disfunsione e di circuiti neurali dei |
DE60020814T2 (de) * | 1999-03-25 | 2006-05-04 | Synthon B.V. | Zolpidem salze |
EP1038875B1 (en) * | 1999-03-25 | 2003-06-04 | Synthon B.V. | Imidazopyridine derivatives and process for making them |
WO2001042239A1 (fr) * | 1999-12-13 | 2001-06-14 | Sumika Fine Chemicals Co., Ltd. | Procede de preparation d'un compose pyridinemethanol |
-
2001
- 2001-04-24 DE DE60125429T patent/DE60125429T2/de not_active Expired - Fee Related
- 2001-04-24 DK DK01930705T patent/DK1292304T3/da active
- 2001-04-24 ES ES04010435T patent/ES2238941T3/es not_active Expired - Lifetime
- 2001-04-24 AT AT01930705T patent/ATE308324T1/de not_active IP Right Cessation
- 2001-04-24 SK SK1637-2002A patent/SK16372002A3/sk not_active Application Discontinuation
- 2001-04-24 JP JP2001577956A patent/JP2003531173A/ja not_active Withdrawn
- 2001-04-24 DE DE60122944T patent/DE60122944T2/de not_active Expired - Fee Related
- 2001-04-24 DE DE04010435T patent/DE04010435T1/de active Pending
- 2001-04-24 US US09/841,025 patent/US20020077332A1/en not_active Abandoned
- 2001-04-24 CA CA002406982A patent/CA2406982A1/en not_active Abandoned
- 2001-04-24 YU YU79402A patent/YU79402A/sh unknown
- 2001-04-24 CZ CZ20023775A patent/CZ20023775A3/cs unknown
- 2001-04-24 WO PCT/US2001/013175 patent/WO2001080857A1/en active IP Right Grant
- 2001-04-24 PL PL01358548A patent/PL358548A1/xx not_active Application Discontinuation
- 2001-04-24 AT AT04010435T patent/ATE335481T1/de not_active IP Right Cessation
- 2001-04-24 AU AU5721301A patent/AU5721301A/xx active Pending
- 2001-04-24 AT AT04010651T patent/ATE338550T1/de not_active IP Right Cessation
- 2001-04-24 DE DE20122435U patent/DE20122435U1/de not_active Expired - Lifetime
- 2001-04-24 NZ NZ522015A patent/NZ522015A/en unknown
- 2001-04-24 PT PT05001922T patent/PT1541146E/pt unknown
- 2001-04-24 ES ES04010651T patent/ES2239558T3/es not_active Expired - Lifetime
- 2001-04-24 DE DE60122216T patent/DE60122216T2/de not_active Expired - Fee Related
- 2001-04-24 ES ES01930705T patent/ES2248321T3/es not_active Expired - Lifetime
- 2001-04-24 DE DE60114617T patent/DE60114617T2/de not_active Expired - Fee Related
- 2001-04-24 EP EP01930705A patent/EP1292304B1/en not_active Revoked
- 2001-04-24 PT PT04010435T patent/PT1473036E/pt unknown
- 2001-04-24 KR KR1020027014220A patent/KR20030069796A/ko not_active Application Discontinuation
- 2001-04-24 ES ES05001922T patent/ES2277301T3/es not_active Expired - Lifetime
- 2001-04-24 IL IL15241101A patent/IL152411A0/xx unknown
- 2001-04-24 SE SE01930705T patent/SE5292304T3/xx unknown
- 2001-04-24 DE DE04010651T patent/DE04010651T1/de active Pending
- 2001-04-24 AT AT05001922T patent/ATE348613T1/de not_active IP Right Cessation
- 2001-04-24 PT PT04010651T patent/PT1475093E/pt unknown
- 2001-04-24 AU AU2001257213A patent/AU2001257213B2/en not_active Ceased
- 2001-04-24 HU HU0300701A patent/HUP0300701A2/hu unknown
-
2002
- 2002-11-15 HR HR20020909A patent/HRP20020909A2/hr not_active Application Discontinuation
-
2004
- 2004-05-24 US US10/853,640 patent/US20040214859A1/en not_active Abandoned
- 2004-05-24 US US10/853,031 patent/US20040220210A1/en not_active Abandoned
- 2004-05-24 US US10/853,338 patent/US20040220212A1/en not_active Abandoned
- 2004-05-24 US US10/853,033 patent/US20040220211A1/en not_active Abandoned
- 2004-05-24 US US10/853,345 patent/US20040220213A1/en not_active Abandoned
- 2004-05-24 US US10/852,912 patent/US20040214858A1/en not_active Abandoned
-
2006
- 2006-02-09 JP JP2006033099A patent/JP2006137778A/ja active Pending
- 2006-06-27 JP JP2006177160A patent/JP2006249105A/ja active Pending
- 2006-10-25 US US11/588,122 patent/US20070037843A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2238941T1 (es) | Solvato de hemitartrato de zolpidem. | |
ES2582646T3 (es) | Formulación de comprimido recubierto y método | |
ES2665539T3 (es) | Derivados de benzamida para inhibir la actividad de ABL1, ABL2 y BCR-ABL1 | |
ES2546847T3 (es) | Formulaciones de un inhibidor de la Src/Abl | |
ES2377066T3 (es) | Composición terapéutica que contiene al menos un derivado de la pirrobenzodiacepina y la fludarabina | |
ES2916604T1 (es) | Ensayos de detección de nrf2 y métodos y composiciones relacionados | |
BRPI0511512A (pt) | derivados pirrolpirimidina úteis no tratamento do cáncer | |
ECSP088405A (es) | Nuevos derivados de pirimidina y su uso en terapia, así como el uso de derivados de pirimidina en la fabricación de un medicamento para la prevención y/o tratamiento de la enfermedad de alzheimer | |
HUP0202367A2 (hu) | FAP-aktivált tumorellenes peptidek, eljárás előállításukra, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk | |
AR049142A1 (es) | Composiciones para recubrimientos de azucar,composiciones recubiertas y metodos para la fabricacion de los mismos | |
HUP0200714A2 (hu) | Gyógyhatású vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
AR120676A1 (es) | Compuestos de benzoti(di)azepina y su uso como ácido biliar | |
PE20020307A1 (es) | Forma de dosificacion de farmaco activada por hidrogel | |
PL2018379T3 (pl) | Sole skopiny oraz ich zastosowanie w sposobach wytwarzania N-demetylo-tiotropium i bromku tiotropium | |
AR053364A1 (es) | Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis | |
MX2009010165A (es) | Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704. | |
AR074739A1 (es) | Comprimidos de capecitabina de disgregacion rapida | |
AR054806A1 (es) | Formulaciones de estrogenos conjugados y bazedoxifeno | |
TW200740764A (en) | Pyrazolone derivatives | |
CO6150122A2 (es) | Comprimidos pediatricos de capecitabina | |
AR095159A2 (es) | Una composición farmacéutica en forma de cápsula para administración oral | |
MX2007001267A (es) | Derivados de naftiridinas 2,8-disustituidas. | |
SI1608346T1 (sl) | Spojine za sproščanje zdravilnih učinkovin na osnovi alfa-hidroksi kislinskih estrov in postopki njihove uporabe | |
TW200800984A (en) | New compounds | |
JP2004505036A5 (es) |